SYNEOS HEALTH UK LIMITED

The Preclinical CRO Market is projected to grow from USD 5.2 billion in 2022 to USD 10.5 billion by 2032, driven by investments in drug discovery and outsourcing to specialized CROs. North America leads with 47.50% share, while Asia Pacific is poised for rapid growth. Key players like Parexel, Labcorp, and Medpace are expanding through strategic alliances and technology advancements, despite regulatory challenges.

GLP-1 drugs like semaglutide and tirzepatide have expanded uses beyond diabetes and weight loss, potentially treating cardiovascular disease, kidney disease, anxiety, depression, and substance use disorder. CRISPR drugs Casgevy for sickle cell disease and β-thalassemia entered the market, though uptake is slow due to complex treatment processes. Protein-folding algorithms by Baker, Hassabis, and Jumper revolutionized biochemical research and pharmaceutical applications. ADCs received significant investment, with firms exploring new linker chemistries. Amylyx Pharmaceuticals pulled an ALS drug after trial failure, continuing research for other uses. Kelly Chibale called for recognizing African scientific potential. Virologists monitored H5N1, mpox, and Marburg outbreaks, with ongoing research and emergency measures. Radiopharmaceuticals saw increased investment and market growth. Evidence suggests vaccines like shingles and flu jabs may protect against dementia.

Prolerity Clinical Research appoints Erica Prowisor as EVP of Transformation and Patient Engagement, and Michael Smith as Chief Commercial Officer. Prolerity operates 11 research sites across Louisiana, Florida, New Jersey, and New York, focusing on complex Phase I–III trials.

The global HIV clinical trials market is projected to grow from USD 1.30 billion in 2024 to USD 2.42 billion by 2034, at a CAGR of 6.4%. Key factors driving growth include increasing HIV infections, R&D investments, drug approvals, and HIV vaccine trials. Phase I trials held the largest revenue share in 2024, while the Asia Pacific region is expected to register the fastest growth. Major companies like Gilead Sciences and Janssen Global Services are significant contributors to the market.

George Clinical appoints Tony Proctor, C.P.A., as CFO, leveraging his 25+ years of financial leadership experience to drive operational excellence and strategic growth.

Sunway Healthcare Group partners with Syneos Health to expand clinical trial capabilities in Malaysia, focusing on improved patient access, operational efficiencies, specialised expertise, and diverse patient engagement.

The bioanalytical testing services market, valued at USD 4.2 Billion in 2022, is projected to reach USD 11.4 Billion by 2032, driven by pharmaceutical R&D and regulatory compliance. North America leads, while Asia-Pacific shows significant growth. Key trends include collaborations, technological advancements, and automation in testing processes.

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology holding the largest revenue share. Key players include IQVIA, Fortrea Inc., PAREXEL, and Thermo Fisher Scientific.

Placeholder text for elements like text, images, lists, etc.